MBX Biosciences (MBX) Assets Average (2024 - 2026)

MBX Biosciences has reported Assets Average over the past 3 years, most recently at $418.9 million for Q1 2026.

  • Quarterly results put Assets Average at $418.9 million for Q1 2026, up 62.86% from a year ago — trailing twelve months through Mar 2026 was $418.9 million (up 62.86% YoY), and the annual figure for FY2025 was $326.8 million, up 85.33%.
  • Assets Average reached $418.9 million in Q1 2026 per MBX's latest filing, up from $392.6 million in the prior quarter.
  • Across five years, Assets Average topped out at $418.9 million in Q1 2026 and bottomed at $238.7 million in Q2 2025.
  • Median Assets Average over the past 3 years was $295.6 million (2024), compared with a mean of $316.5 million.
  • The largest annual shift saw Assets Average soared 42.52% in 2025 before it surged 62.86% in 2026.
  • Over 3 years, Assets Average stood at $275.5 million in 2024, then skyrocketed by 42.52% to $392.6 million in 2025, then grew by 6.7% to $418.9 million in 2026.
  • Business Quant data shows Assets Average for MBX at $418.9 million in Q1 2026, $392.6 million in Q4 2025, and $315.8 million in Q3 2025.